Navellier & Associates Inc Lantheus Holdings, Inc. Transaction History

Navellier & Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$51.07 - $68.26 $131,913 - $176,315	2,583 Added 13.46%	21,774 $1.36 Million
Q4 2023 Feb 08, 2024	BUY	$55.6 - $77.89 $129,937 - $182,028	2,337 Added 13.87%	19,191 $1.19 Million
Q3 2023 Nov 09, 2023	SELL	$60.27 - $90.75 $179,484 - $270,253	-2,978 Reduced 15.02%	16,854 $1.17 Million
Q2 2023 Aug 07, 2023	BUY	$82.41 - $99.65 $44,831 - $54,209	544 Added 2.82%	19,832 $1.66 Million
Q1 2023 May 12, 2023	SELL	$47.76 - $82.86 $9,886 - $17,152	-207 Reduced 1.06%	19,288 $1.59 Million
Q4 2022 Feb 02, 2023	BUY	$48.76 - $77.67 $372,818 - $593,864	7,646 Added 64.53%	19,495 $993,000
Q3 2022 Nov 09, 2022	BUY	$61.42 - $86.29 $277,556 - $389,944	4,519 Added 61.65%	11,849 $833,000
Q2 2022 Aug 12, 2022	BUY	$55.54 - $72.65 $407,108 - $532,524	7,330 New	7,330 $484,000

495

67.2M

1.19M

829K

Ticker LNTH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 68,741,904
Market Cap $7.38B
Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for n...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.